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Introduction 
 
The thirty-fifth meeting of the World Health Organization (WHO) 
Expert Committee on Drug Dependence (ECDD) took place in 
Hammamet, Tunisia from 4 to 8 June 2012.  
 
Dr Willem Scholten, Team Leader, Access to Controlled Medicines, 
WHO, opened the meeting on behalf of Dr Carissa F. Etienne, 
Assistant Director-General, Health Systems and Services. He 
welcomed all participants on behalf of the Director-General. He noted 
that the thirty-fifth meeting of the ECDD was in many respects special. 
It was the first ECDD meeting organized in line with the revised 
Guidance on the WHO review of psychoactive substances for 
international control (1) adopted by the WHO Executive Board in 
January 2010. Rules on the transparency of the process as a whole 
were introduced and, for the first time, all meeting documents were 
published on the WHO ECDD meeting website before the meeting. 
Further, all reviews on substances under evaluation were peer reviewed 
by experts, and the results of these reviews were also made available in 
the public domain prior to the meeting. 
 
In general terms, the role of WHO is the assessment of medical 
properties and the liability for abuse of any substance, pure chemical or 
plant material, and to advise the United Nations Commission on 
Narcotic Drugs (CND) on which substances should be under 
international control. The purpose of this meeting of the ECDD was, 
therefore, to review a number of substances and to provide its advice to 
WHO on whether these substances should be recommended for 
scheduling under the international drug control conventions (in case of 
critical reviews) and recommend whether a critical review should be 
held at a subsequent meeting of the ECDD (in case of a pre-review). 
ECDD is mandated to draft recommendations to facilitate WHO’s 
advisory role to the CND, attributed by the Single Convention on 
Narcotic Drugs, 1961 (2) and the Convention on Psychotropic 
Substances, 1971 (3). Although the primary mandate of the ECDD is 
the evaluation of psychoactive substances for international control, it 
also has to address other related scientific issues at its meeting. 
 
Dr Scholten reminded the members of the ECDD that they serve as 
independent scientists and therefore they advise WHO in their 
individual capacity as experts and not as representatives of their 
government or organization. The experts were invited to deliberate on 
the issues, providing their best expertise and knowledge, to come to 
recommendations that will benefit the world as a whole.  
 
The agenda as proposed by the Secretariat was accepted. The Expert 
Committee elected the Chair, Co-chair and Rapporteur. The Chair 
welcomed all participants. He reminded them that finding a proper 
balance between maintaining availability of psychoactive substances 
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for medical purposes, while minimizing abuse of such substances is 
important. He requested the Expert Committee to consider both aspects 
equally while making decisions. The Chair reminded the Expert 
Committee that all recommendations should be unanimously agreed 
upon if possible. In the event that a member has a divergent opinion, 
he or she can request the Rapporteur to include a special statement in 
the report. The Expert Committee appreciated the convening of the 
meeting after a six-year hiatus. 
 
Before the discussions began, all Members of the Expert Committee 
and all temporary advisers attending the meeting were requested to 
declare any conflicts of interest. No declaration of conflicts of interest 
is required for observers. Mrs De Lima declared that as the Executive 
Director of the International Association for Hospice and Palliative 
Care (IAHPC), she has advocated the elimination of undue barriers to 
the rational medical use of controlled substances, in particular the use 
of opioids for pain relief. The IAHPC works with patients and health-
care providers around the world and the outcomes of this meeting and 
its recommendations may have consequences for patients and care 
providers worldwide. Dr Pennings declared that he is a member of the 
Risk Assessment Committee on New Drugs of the Netherlands. Mr 
Dasgupta declared that he is a paid member of the Risk Safety 
Advisory Board of Covidien. In 2011, he also consulted for Pfizer 
during a one-day meeting on general non-product-specific 
epidemiological methods in pharmacovigilance. Dr Edwards declared 
that the research he presented at the meeting was funded under the 
European Union (EU) Monitoring Medicines Project FP7, Grant No 
223566. The other Members and temporary advisers declared that they 
had no conflicts of interest. 
 
The declared potential conflicts of interest were considered not to 
conflict with any agenda items discussed at the meeting or with the 
recommendations issued by the Committee. 
 
Dr Galina Korchagina, observer for the International Narcotics Control 
Board (INCB), informed the Committee of the role of the Board. The 
Board was established in 1961 as an independent treaty body. It 
consists of 13 members elected by the Economic and Social Council 
(ECOSOC), three of whom are chosen from candidates nominated by 
WHO. Its mandate is to monitor and promote compliance with the 
three international drug control conventions. Its functions are to ensure 
availability of controlled substances for legal demands, and to prevent, 
if possible, illicit activities related to these substances. These functions 
should be seen in the light of the preambles of the Single Convention 
on Narcotic Drugs and the Convention on Psychotropic Substances, 
both of which state that the substances under control are indispensable 
for medical and scientific purposes. Dr Korchagina also gave an 
overview of the various reports and publications of the Board, 
including one of the most recent, the Guide on Estimating 
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Requirements for Substances under International Control (4), jointly 
developed by WHO and INCB. 
 
 
1. Revision of guidelines 
The Committee was informed that the Executive Board, at its 126th 
Session in January 2010, had adopted the revised document that 
contains specific guidance for substance evaluation and conduct of the 
ECDD, supplementary to the WHO regulations guiding Expert 
Advisory Panels and Committees, in general (5). The specific guidance 
was developed initially in 1986 and updated in 1990, 1994, 1999 and 
2000. Subsequently, a proposal for supplementary guidelines, made at 
the request of the Expert Committee, was rejected by the WHO 
Executive Board in 2004 and 2005. The Board then invited the 
Secretariat and the Expert Committee to develop revised guidelines, 
which resulted in the Guidance on the WHO review of psychoactive 
substances for international control. The title of the document was 
changed, and the phrase “dependence-producing” was deleted, as that 
term suggests that it had already been established that the substances 
under review were dependence-producing. 
The revision was drafted by a working group consisting of six 
representatives of Member States from four regions, and three experts 
from the Expert Advisory Panel on Drug Dependence (Dependence 
Liability Evaluation), in May 2007. Six invited observers also 
attended. The document was posted for public comment. Comments 
from individuals, nongovernmental organizations and other bodies 
were taken into consideration in the next draft, which was also posted 
on the Internet for public comment. These comments were also 
considered by the Secretariat in drafting the final proposal to the 
Executive Board.  
The revised Guidelines are aimed to ensure that the WHO review 
process is based on scientific and public health-related principles. The 
current revision provides additional transparency and clarity to the 
process and procedures as a whole. In particular, it includes current 
best practices for assessing substances for their abuse liability, 
methodology for the Expert Committee to use to arrive at its decisions, 
and procedures for reporting and for publishing reports.  
According to the Guidelines, information will be presented in a way 
that will facilitate evidence-based assessment; peer reviews will be 
made available to the Expert Committee in advance of the meeting. 
The new confidentiality provisions will help prevent pre-emptive or 
inaccurate disclosure of the Expert Committee’s recommendations. 
The revision clarifies that the same criteria apply for the assessment of 
substances not previously scheduled as for those being considered for 
rescheduling. 
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2. Work of international bodies concerned with controlled substances 
The Committee was informed of the important events in the work of 
international bodies concerned with controlled substances since the 
thirty-fourth meeting of the ECDD (6).  
 
WHO recommendations on oripavine and dronabinol were discussed at 
the fiftieth session of the CND in March 2007, where the 
recommendation to place oripavine in Schedule I of the Single 
Convention was accepted in decision 50/1 (7). 
 
However, the WHO recommendation to move dronabinol and its 
stereoisomers from Schedule II to Schedule III of the 1971 Convention 
was rejected and WHO was requested to reconsider this issue in 
decision 50/2 (8). The Expert Committee noted that the Conventions 
allow the CND to decide differently from a WHO recommendation, 
based on considerations other than the medical and scientific ones 
considered by the ECDD. There was discussion on whether the ECDD 
should revisit the recommendation on dronabinol made at the thirty-
fourth meeting, as requested by the CND at its fiftieth session, 
following its decision not to adopt the WHO recommendation to 
change the schedule from II to III. After discussion, the Expert 
Committee decided that the previous ECDD decision on dronabinol 
should stand. The Expert Committee was unaware of any new 
evidence that was likely to materially alter the scheduling 
recommendation made at its thirty-fourth meeting. 
 
Resolutions related to ketamine were also discussed. The Expert 
Committee was informed that having already adopted resolution 49/6 
in 2006 (9), CND adopted another resolution 50/3 in 2007 (10). The 
INCB made recommendations in its annual reports in 2007 (11), 2008 
(12) and 2009 (13), that all countries consider scheduling ketamine at a 
national level. 
 
In 2012, at the fifty-fifth session of the CND, Resolution 55/1 (14) on 
new psychoactive substances was adopted. This Resolution includes a 
paragraph calling on WHO to resume substance evaluation work and a 
paragraph inviting the countries to fund the activities mentioned in the 
Resolution. Making funding for continuing ECDD activities 
sustainable was also discussed in the plenary of the CND. Several 
countries showed interest in providing resources. 
 
The ECDD acknowledged the additional resolutions since the last 
ECDD meeting, and noted that while they do not have direct impact on 
the scheduling decisions of the ECDD, they are part of the broader 
context of international drug policy. 
 
The Expert Committee noted from the pertinent provisions in the 
international drug control conventions and the guidance on substance 
evaluation, that the involvement of WHO is indispensable in the 
process of scheduling of a substance for international control, and that 
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it will only recommend scheduling after scientific evaluation by the 
ECDD. 
 
3. Critical review of psychoactive substances 
 
A critical review is conducted by the Expert Committee in any of the 
following cases:  
1. There has been notification from a Party to the 1961 Single 
Convention on Narcotic Drugs and the 1971 Convention on 
Psychotropic Substances concerning the scheduling of a 
substance.  
2. There has been an explicit request from the United Nations 
CND to review a substance.  
3. Pre-review of a substance has resulted in a recommendation for 
critical review.  
4. Information is brought to the attention of WHO by any party 
that a substance presenting an especially serious risk to public 
health and society, and of no recognized therapeutic use is 
clandestinely manufactured.  
 
If therapeutic use of the substance is confirmed subsequently by 
any party in respect of case 4, the substance shall be subject to a 
pre-review. 
 
Two substances under critical review at the thirty-fifth meeting 
(γ-hydroxybutyric acid (GHB) and ketamine) had been examined at the 
thirty-fourth meeting and recommended for critical review (6). 
 
 
3.1 Substance recommended for change in scheduling 
 
γ-Hydroxybutyric acid (GHB) 
This section provides information additional to the information 
presented in the report of the thirty-fourth meeting (6). The Expert 
Committee discussed GHB in the context of γ-butyrolactone (GBL) 
and 1,4-butanediol (1,4-BD), precursors of GHB, see sections 4.4 and 
4.5. 
 
Substance identification and pharmacodynamics 
γ-Hydroxybutyric acid (GHB), also known as 4-hydroxybutanoic acid 
and sodium oxybate, is a naturally occurring substance found in low 
concentrations in mammalian tissues. It is considered to act by binding 
to GHB-specific receptors and γ-aminobutyric acid B (GABAB) 
receptors. At pharmacological doses it acts as a central nervous system 
depressant.  
 
Previous reviews 
GHB was pre-reviewed during the thirty-first (15) and thirty-second 
(16) meetings, held in 1998 and 2000, respectively. In 2001, GHB was 
placed in Schedule IV of the 1971 Convention by a decision of the 
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CND. It was again pre-reviewed at the thirty-fourth ECDD meeting in 
2006 (6), at which time the Expert Committee recommended a new 
critical review to consider its possible rescheduling.  
 
Evidence on dependence potential 
The Expert Committee examined additional information from the 
updated critical review report and peer-review reports. The Expert 
Committee noted that there is compelling evidence that dependence on 
GHB exists in humans and noted withdrawal syndromes and 
withdrawal seizures. 
 
Actual abuse 
The Expert Committee noted that at present, GHB appears to be 
mainly used and abused in the United States of America, Europe and 
Australia. Most GHB used illicitly originates from clandestine 
manufacture.  
 
In their discussions, the Expert Committee and advisers agreed on the 
narrow margin of safety of GHB. There have been numerous reports 
from Europe and the United States of accidental fatal and non-fatal 
overdoses where GHB was implicated, both when used alone and with 
other substances. 
 
The Expert Committee also noted there have been reports of GHB 
being used to facilitate sexual assault. 
 
Therapeutic usefulness 
GHB is used as a medicine in some countries on a small scale for 
various indications. GHB is not included in the WHO Model List of 
essential medicines (17). 
 
Need for the substance for other purposes (e.g., industrial) 
The Expert Committee acknowledged the use of GHB in the 
production of a wide variety of industrial polymers.  
 
Measures taken by countries to curb abuse 
The Expert Committee was made aware of measures taken by 30 out of 
the 51 countries that responded to the questionnaire circulated by 
WHO in 2008 in preparation for the meeting. For example, Norway is 
planning to implement legal limits for driving under the influence of 
non-alcohol drugs including GHB. In the United States, GHB 
(Xyrem
®
) is available for the treatment of narcolepsy in association 
with an extensive risk management programme. Postmarketing data 
from this programme show minimal abuse or diversion of this product. 
The Netherlands recently re-assessed the risk potential of GHB and 
found it to be moderate to high. On this basis GHB was upgraded to 
List 1 (hard drugs) of the Dutch Opium Act. 
 
16 
 
Recommendation 
The Expert Committee considered the implications of rescheduling this 
substance. On the basis of available data on its toxicity and dependence 
potential, the Committee rated the abuse liability of GHB to be 
substantial, whereas the therapeutic usefulness is little to moderate. 
The Committee therefore came to the conclusion that GHB should be 
moved from Schedule IV to Schedule II of 1971 Convention. 
 
3.2  Other substance critically reviewed 
 
 Ketamine (INN) 
Substance identification 
Ketamine (INN) is (±)-2-(o-chlorophenyl)-2-(methylamino)-
cyclohexanone. It contains a chiral centre, resulting in two 
enantiomers: S-(+)-ketamine and R-(–)-ketamine. Usually, the 
racemate is marketed, but the more active S-(+)-enantiomer is 
increasingly present in commercially available preparations. 
 
Previous reviews 
During its thirty-third meeting in September 2002, the ECDD pre-
reviewed ketamine (18). Based on the available information, a 
recommendation was made for a critical review of this substance. 
During its thirty-fourth meeting, the ECDD discussed the critical 
review report on ketamine and concluded that this information was not 
sufficient to warrant scheduling (6). The Committee therefore 
requested the Secretariat to produce an updated version of the critical 
review for the thirty-fifth meeting.  
Evidence on dependence potential 
Ketamine may produce dependence in animal models, but reports of 
dependence in humans are rare and largely limited to health-care 
professionals with access to ketamine. The short duration of action 
makes it difficult to maintain intoxication for sustained periods. 
Tolerance may occur, but there is insufficient evidence to show that 
ketamine causes a withdrawal syndrome in humans. 
 
Actual abuse 
Information on ketamine is not routinely collected in population 
surveys and morbidity and mortality data collection systems. Levels of 
use in the general population, however, appear to be very low with 
higher levels in groups with access to the substance (e.g., medical and 
veterinarian professionals) and party drug users. Ketamine is difficult 
to synthesize, so illicit production is rare in most countries. However, 
representatives of the INCB and United Nations Office on Drugs and 
Crime (UNODC) reported that illicit production of ketamine is of 
increasing concern in China and India. China reported an increase in 
the chronic use of ketamine among young adults, particularly in Macao 
and Hong Kong. The chronic use of ketamine was associated with 
urinary tract dysfunction. In the United States, a national survey of 
schoolchildren showed that ketamine use has remained very low and 
steady since 2007, and data from hospital emergency departments 
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suggest that ketamine-related visits constitute fewer than one out of 
every 2000 visits caused by illicit drug use per year.  
 
Therapeutic usefulness 
Ketamine is widely used as an anaesthetic in human and veterinary 
medicine, and is included in the WHO Model List of essential 
medicines (17) and WHO Model List of essential medicines for 
children (19). Compelling evidence was presented about the prominent 
place of ketamine as an anaesthetic in developing countries, 
particularly in Africa. The ease of parenteral administration gives 
ketamine a major advantage when anaesthetic gases are impossible to 
use due to limited equipment and a lack of appropriately trained 
specialists. In many countries there are no suitable alternatives that are 
affordable. 
 
Recommendation 
Ketamine is a widely used anaesthetic, especially in developing 
countries, because it is easy to use and has a wide margin of safety 
when compared with other anaesthetic agents. While the Expert 
Committee acknowledged the concerns raised by some countries and 
UN organizations, ketamine abuse currently does not appear to pose a 
significant global public-health risk. Concerns were raised that if 
ketamine were placed under international control, this would adversely 
impact its availability and accessibility. This in turn would limit access 
to essential and emergency surgery, which would constitute a public-
health crisis in countries where no affordable alternative anaesthetic is 
available. On this basis, the Expert Committee decided that bringing 
ketamine under international control is not appropriate. Furthermore, it 
noted that some countries have already placed this medicine under 
control. Countries with serious abuse problems may decide to maintain 
control measures, but should ensure ready access to ketamine for 
surgery and anaesthesia for human and veterinary care.  
 
4. Pre-review of psychoactive substances 
The review of psychoactive substances by WHO is carried out in two 
steps. The first step is referred to as pre-review; this is a preliminary 
review carried out by the Committee to determine whether or not a 
fully documented review (critical review) of the substance is required. 
The criterion for judgement as to whether critical review is necessary 
is whether or not WHO has information that might justify the 
scheduling of the substance. In the case of psychotropic substances, 
this requires information on actual abuse of the drug, which causes 
significant public health and social problems. 
 
In addition to the Secretariat, any member of the Expert Committee, or 
any representative of the other organizations invited to participate in 
the Expert Committee meeting, can submit a proposal to pre-review a 
substance together with supporting information.  
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Prior to the thirty-fifth meeting of the ECDD, the Secretariat submitted 
each of the pre-review reports to an expert for peer review and made 
them available on the Internet. 
 
4.1  Dextromethorphan (pINN) 
Dextromethorphan is (+)-3-methoxy-17-methyl-(9α,13α,14α)-
morphinan. During the fourth meeting of the ECDD in 1953 (then: 
Expert Committee on Drugs Liable to Produce Addiction), the 
synthetic substances of the morphinan type, including 
dextromethorphan, were discussed (20). After reviewing the 
worldwide reports at that time, the Expert Committee concluded that 
dextromethorphan has no morphine-like actions, lacks the ability to 
sustain morphine dependence, and exhibited no signs of dependence 
liability. Therefore, the Expert Committee recommended against 
placing dextromethorphan under control of the Conventions. In order 
to update the scientific evidence on dextromethorphan, a member of 
the Expert Committee proposed that it be pre-reviewed. 
 
Dextromethorphan is the d-isomer of the codeine analogue 
methorphan; however, unlike the l-isomer, it does not act through 
opioid receptors. Dextromethorphan binds with high affinity to sites 
associated with sigma ligands and low affinity to the phencyclidine 
(PCP) binding site of the N-methyl-D-aspartate (NMDA) receptor. The 
relationship of these receptor binding sites to the pharmacological 
mechanism of the antitussive effects of dextromethorphan is not 
known. Dextromethorphan produces PCP-like discriminative stimulus 
effects in rats and partial substitution for PCP in monkeys probably 
produced by the metabolite dextrorphan. Dextromethorphan can alter 
self-administration of several substances of abuse such as morphine, 
cocaine, and methamphetamine. Few data exist on dextromethorphan 
dependence, with only a handful of cases described in scientific 
literature. Cases of abuse of dextromethorphan have been reported in 
several countries. However, these reports are still relatively infrequent. 
Dextromethorphan is produced commercially in many regions of the 
world, but synthesis is a complex and time-consuming process, making 
clandestine production impractical. Dextromethorphan is widely used 
as an antitussive in many over-the-counter and prescription-only 
preparations. 
 
Recommendation 
Following review of the documents presented at the thirty-fifth 
meeting, the Expert Committee concluded that the abuse potential of 
dextromethorphan is relatively low, intoxications are rare, and reports 
of dependence are infrequent. Dextromethorphan is widely used as an 
antitussive agent and placing it under international control could 
negatively impact its availability for medical use. On this basis, the 
Expert Committee concluded that a critical review is not warranted at 
this time.  
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4.2  Tapentadol (INN) 
Tapentadol is 3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-
phenol hydrochloride. Tapentadol has two chiral centres and is 
manufactured as a single (R,R) stereoisomer. Tapentadol shares a 3-(3-
hydroxyphenyl)propylamino structural fragment with morphine and its 
analogues. It is a novel analgesic agent with activity at the μ-opioid 
receptor and norepinephrine reuptake inhibition. Immediate release and 
extended release formulations of tapentadol are indicated for analgesia. 
Tapentadol demonstrates improved gastrointestinal tolerability 
(specifically in the incidence of nausea, vomiting, and constipation) 
compared with strong opioids at doses providing similar analgesia. 
Dependence has been demonstrated in animal models, but the level of 
dependence relative to morphine is not known. Mild withdrawal was 
observed in clinical trials submitted for the initial approval of 
tapentadol. Tapentadol has only been marketed since 2009 and 
therefore has not appeared in many substance use surveys or 
surveillance reports. Overall, toxicity for tapentadol does not appear to 
be greater than that for other μ-opioid receptor agonists. In the 3 years 
since tapentadol was launched in the United States, analyses of 
postmarketing surveillance data show lower abuse than oxycodone and 
slightly higher abuse than tramadol. The Expert Committee noted that 
tapentadol has been scheduled or recommended for scheduling in 
Australia, Germany, the Netherlands, New Zealand, Switzerland, the 
United States and the United Kingdom.  
 
Recommendation 
Given the action of tapentadol at the μ-opioid receptor, together with 
some evidence of abuse, the Expert Committee recommended that a 
critical review be conducted. 
 
 4.3 Piperazines 
 
4.3.1 N-Benzylpiperazine (BZP) 
N-Benzylpiperazine (BZP) is 1-benzylpiperazine. It is a piperazine 
derivative with stimulant properties (including euphoria). Animal 
studies have shown that BZP stimulates the release and inhibits the 
reuptake of dopamine, serotonin and noradrenaline, but dopaminergic 
and serotonergic effects predominate. In studies, BZP was found to be 
less potent than methylenedioxymethamphetamine (MDMA), 
methamphetamine or amphetamine. BZP has never been licensed as a 
medicine but was found to be an active metabolite of a proposed anti-
depressant (piberaline, a product that was later not marketed). Abuse 
was first reported in the late 1990s in the USA and Scandinavia but has 
since been reported in other countries (particularly in Australia, Europe 
and New Zealand). The behavioural effects of BZP include 
amphetamine-like effects. Many suppliers of BZP market the 
substance as “legal ecstasy” or as a “legal high”. Such products 
typically contain other piperazine derivatives in variable quantities. 
Toxic effects have been reported (agitation, tachycardia and seizures) 
with associated hospital admissions, but cases involving BZP alone are 
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rare. Although BZP has been found in substance-related deaths, in the 
vast majority of instances, other commonly abused substances were 
also present; therefore the role of BZP in these deaths is unclear.   
 
Recommendation 
Based on the reported psychostimulant effects, evidence of abuse, and 
adverse effects, the Expert Committee concluded that a critical review 
of N-benzylpiperazine is warranted. 
 
4.3.2 1-(3-Trifluoromethylphenyl)piperazine (TFMPP) 
1-(3-Trifluoromethylphenyl)piperazine (TFMPP) is a piperazine 
derivative with mild stimulant effects and hallucinogenic properties. 
TFMPP has never been licensed as a medicine but is a known 
metabolite of a previously used anti-inflammatory analgesic 
(antrafenine). Its use was first reported in the late 1990s in Scandinavia 
and the United States along with BZP, but has since been reported in 
various other countries (particularly Europe and New Zealand). Many 
suppliers of TFMPP market the substance as “legal ecstasy” or as a 
“legal high”. Such products typically contain other piperazine 
derivatives in variable quantities. Very few user reports involving the 
use of TFMPP alone have been documented. However, the toxic 
effects reported include: nausea, hallucinations and slight tremors. 
Hospital admissions have occurred, but all involved other substances 
(including piperazines). Although TFMPP has been found in drug-
related deaths, in the vast majority of instances, other substances of 
abuse were also present; therefore the role of TFMPP in these deaths is 
unclear. Animal studies have indicated that TFMPP is unlikely to 
possess abuse or dependence potential, but there are no human clinical 
studies to support this. 
 
Recommendation 
1-(3-Trifluoromethylphenyl)piperazine does not appear to have abuse 
and dependence potential. On this basis, the Expert Committee decided 
that a critical review is not warranted at this time. 
 
4.3.3 1-(3-Chlorophenyl)piperazine (mCPP) 
1-(3-Chlorophenyl)piperazine (mCPP) is a piperazine derivative with 
stimulant (including euphoric) and hallucinogenic properties. mCPP 
has never been licensed as a medicine but is a known metabolite of 
some antidepressants and is a tranquillizer. Its use was first reported in 
the mid-2000s across Europe but has since been reported in various 
other countries (e.g., the United States). mCPP is sometimes sold as 
“legal ecstasy” or as a “legal high” or as “ecstasy” itself. Such products 
can contain other piperazine derivatives as well as other psychoactive 
substances including MDMA. Very few user reports involving the use 
of mCPP alone have been documented. However, the toxic effects 
reported include: nausea, hallucinations, headache and most frequently, 
anxiety and panic attacks. There are no published reports of non-fatal 
or fatal hospital admissions. In Europe, a few cases reported to 
monitoring centres have mentioned hot flushes, some respiratory 
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problems and coma, but all these cases also involved other unspecified 
substances. No specific studies have been performed to determine the 
abuse or dependence potential of mCPP but, in animal discrimination 
studies, it has been found to mimic TFMPP, ethanol and MDMA, but 
not lysergic acid diethylamide (LSD). Its abuse and dependence 
potential in humans is unclear. 
 
Recommendation 
The Expert Committee considered the information contained in the 
pre-review, and found that there is a paucity of data on 1-(3-
chlorophenyl)piperazine. Furthermore its abuse and dependence 
potential in humans remains unclear. On this basis, the Expert 
Committee concluded that a critical review is not warranted at this 
time. 
 
4.3.4 1-(4-Methoxyphenyl)piperazine (MeOPP) 
1-(4-Methoxyphenyl)piperazine (MeOPP) is a piperazine derivative 
that appears to have mild stimulant effects (including euphoria) and 
some hallucinogenic properties. Very little information is available on 
this substance. MeOPP has never been licensed as a medicine. The first 
report of seized material containing MeOPP appeared in 2006 in the 
United Kingdom. Many suppliers market the substance as “legal 
ecstasy” or as a “legal high”. Such products typically contain other 
piperazine derivatives in variable quantities. There are no published 
reports of non-fatal or fatal hospital admissions. No specific studies 
have been performed to determine the abuse or dependence potential. 
 
Recommendation 
Given the limited information available, and the current lack of 
evidence of abuse, the Expert Committee recommended that a critical 
review for 1-(4-methoxyphenyl)piperazine not be conducted at this 
time. 
 
4.3.5 1-(3,4-Methylenedioxybenzyl)piperazine (MDBP) 
1-(3,4-Methylenedioxybenzyl)piperazine (MDBP or MDBZP) is a 
piperazine derivative but its effects are largely unknown. MDBP has 
never been licensed as a medicine but is a metabolite of a withdrawn 
nootropic medicine, fipexide. This medicine was withdrawn because it 
had adverse toxic effects (fever and hepatotoxicity). Use of MDBP has 
been noted by governmental organizations in the United States but 
there are no reports from other countries. There are no published 
reports of non-fatal or fatal hospital admissions. No specific studies 
have been performed to determine the abuse or dependence potential of 
MDBP. 
 
Recommendation 
Based on the lack of animal, human clinical, and epidemiological data 
on the abuse and dependence potential of MDBP, the Expert 
Committee did not recommend a critical review of 1-(3,4-methylene-
dioxybenzyl) piperazine at this time. 
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4.4  γ-Butyrolactone (GBL) 
γ-Butyrolactone (GBL) is oxolan-2-one. The pre-review of GBL was 
decided on the basis that GBL can be readily converted both 
chemically and in the body to GHB. GHB is a controlled substance 
under the 1971 Convention, and was subject to a critical review at the 
thirty-fifth meeting of the ECDD. The Expert Committee discussed 
GBL in the context of GHB and 1,4-butanediol (1,4-BD), another 
precursor of GHB, see sections 3.1 and 4.5. GBL is widely used as a 
solvent and reagent in the chemical industry. Since the end of the 
1990s, reports of abuse of GBL have emerged, mainly from Australia, 
Europe and the United States. The epidemiology of the abuse of GBL 
is intrinsically linked to that of GHB since GBL is rapidly metabolized 
to GHB. A few deaths have been documented, but owing to the rapid 
metabolism it is difficult to establish whether GHB, GBL or 1,4-BD 
was consumed. Several cases of withdrawal from GBL, 1,4-BD and 
GHB have been documented. The new controls rapidly curtailed the 
previously open sale of GHB. This may also help to explain the 
emergent use of GBL, which does not currently fall under the controls 
of the international drug control convention. In view of concerns about 
the diversion of GBL and 1,4-BD for conversion to GHB, some 
Member States have chosen to control GBL, 1,4-BD, or both, under 
drug control or equivalent legislation and voluntary measures to 
prevent diversion.  
 
Recommendation 
Based on the evidence presented in the pre-review of GBL, its close 
association with GHB, and the recommendation made by the Expert 
Committee to reschedule GHB from Schedule IV to Schedule II of the 
1971 Convention, the Committee recommended that a critical review 
of GBL be undertaken. 
 
4.5  1,4-Butanediol (1,4-BD) 
The pre-review of 1,4-BD was conducted on the basis that 1,4-BD can 
be readily converted both chemically and in the body to GHB. GHB is 
a controlled substance under the 1971 Convention, and was subject to a 
critical review at the thirty-fifth meeting of the ECDD. The Expert 
Committee discussed 1,4-BD in the context of GHB and GBL, another 
precursor of GHB, see sections 3.1 and 4.4. 1,4-BD is an industrial 
chemical and an important raw material widely used in the chemical, 
pharmaceutical, textile, paper making, and motor vehicle industries. 
Starting in the 1990s, it is believed that national controls on GHB 
prompted substitution of 1,4-BD and GBL for GHB as drugs of abuse. 
The epidemiology of the abuse of 1,4-BD is intrinsically linked to that 
of GHB since 1,4-BD is rapidly metabolized to GHB. A few deaths 
have been documented, but owing to the rapid metabolism it is difficult 
to establish whether GHB, GBL or 1,4-BD was consumed. It appears 
to be mainly used and abused in Australia, Europe, and the United 
States. The new controls rapidly curtailed the previously open sale of 
GHB. They may also help to explain the emergent use of 1,4-BD, 
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which does not currently fall under the controls of the international 
drug control convention. In view of concerns about the diversion of 
GBL and 1,4-BD for conversion to GHB, some Member States have 
chosen to control GBL, 1,4-BD, or both, under drug control or 
equivalent legislation and voluntary measures to prevent diversion. 
 
Recommendation 
Based on the evidence presented in the pre-review of 1,4-BD, its close 
association with GHB, and the recommendation made by the Expert 
Committee to reschedule GHB from Schedule IV to Schedule II of the 
1971 Convention, the Committee recommended that a critical review 
of 1,4-BD be undertaken. 
 
 
5. Issues identified for consideration at future ECDD meetings 
 
The Expert Committee was informed that the Secretariat was likely to 
propose several substances for inclusion on the agenda of a future 
ECDD meeting: 
 
 The Commission on Narcotic Drugs, in its resolution 52/5 Exploration 
of all aspects related to the use of cannabis seeds for illicit purposes 
requested cannabis be reviewed (21).  
 Noting the concerns of the CND expressed in Resolution 55/1, 
Promoting international cooperation in responding to the challenges 
posed by new psychoactive substances (14)  and Resolution 53/11, 
Promoting the sharing of information on the potential abuse of and 
trafficking in synthetic cannabinoid receptor agonists (22), the 
Secretariat is planning to carry out reviews of mephedrone and of 
synthetic cannabinoids. 
 Furthermore, the Secretariat was notified by the Secretary-General, 
United Nations, of the exemption by the Government of Germany of 
one cathine preparation and six flunitrazepam preparations from 
certain provisions under the 1971 Convention and this will be proposed 
for assessment according to Article 3 paragraph 4 of the Convention on 
Psychotropic Substances and paragraph 61 of the Guidance on the 
WHO review of psychoactive substances for international control (1).  
 
One expert proposed the pre-review of zolpidem, which is currently in 
Schedule IV of the 1971 Convention. This will be included in the list 
of future pre-reviews. 
 
There was a brief discussion as to whether ethanol (ethyl alcohol) 
should be considered for pre-review. The Secretariat informed the 
Expert Committee that WHO Secretariat and Member States are in the 
process of implementing the WHO Global Strategy to Reduce the 
Harmful Use of Alcohol, which was adopted by the World Health 
Assembly (WHA) in 2010 (Resolution WHA63.13) (23). Noting this, 
the Expert Committee referred the matter for consideration at a future 
Expert Committee meeting. 
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The Australian National Council on Drugs, a government-appointed 
expert panel, requested that the Secretariat consider reviewing 
levacetylmethadol (LAAM) at a future meeting. Their request was not 
based on its status under international control, but rather to determine 
if a recommendation should be made regarding access to this medicine 
for the management of opioid dependence. It is possible that the 
availability of LAAM may improve access to management of opioid 
dependence. 
 
 
6. Other matters 
 6.1  Use of terms  
The Expert Committee noted that revision of the International 
Classification of Diseases (ICD) is presently under way, and planned 
for submission for approval to the World Health Assembly in 2015. 
The current discussions by the pertinent groups of experts indicate that 
the relevant terms and their general definitions and meaning in the 
tenth revision (ICD-10) are likely to be retained in the eleventh 
revision (ICD-11). The Committee discussed the terms related to the 
work of the ECDD, their meanings, and development of terminologies 
for substance evaluation in the decades since the Single Convention on 
Narcotic Drugs and the Convention on Psychotropic Substances were 
adopted. The issues discussed are contained in the Annex 
(Developments in terminology: the drug treaties, scheduling criteria, 
and diagnostic terms). The Expert Committee agreed that several 
topics require further deliberation, and additional aspects may need to 
be considered. 
 
The Expert Committee further recognizes that there is much stigma 
around drug use and drug use disorders, and that occasional changes in 
terminology may be needed to meet the goal of humane and respectful 
treatment for patients. 
 
The Committee decided that redefining terminologies for substance 
evaluation requires thorough preparation and discussion of wording by 
multiple experts, followed by a proposal to the Committee which 
would be distributed well in advance. The Committee invited the 
Secretariat to organize the debate and to propose the issue of 
terminology for consideration again at its thirty-sixth meeting. 
 
The Expert Committee recommended revisiting the definitions found 
in the 1994 Lexicon of alcohol and drug terms (24), as well as those in 
ICD-11, with the intention of providing further clarification on how 
this terminology relates to the terms used in the international drug 
control system. This should result in an updated version of the 
Lexicon. 
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6.2 Use of pharmacovigilance data for the assessment of abuse 
and dependence potential  
 
During its thirty-fourth meeting, the ECDD discussed the use of 
pharmacovigilance data as a potential source to inform scheduling 
decisions. Accordingly, the Secretariat organized a discussion with 
experts on drug dependence assessment and pharmacovigilance in 
2007, and the WHO Uppsala Monitoring Centre (UMC) undertook a 
study to identify indicators of drug abuse and dependence potential 
from its database, VigiBase
TM
. During the thirty-fifth meeting of the 
ECDD, a representative of the UMC presented the results of analyses 
which the Expert Committee used to assess the utility of 
pharmacovigilance data in making scheduling decisions.  
 
After examining the analyses conducted by the UMC, the Expert 
Committee considered that refinement of the methodology is 
warranted. However, it was noted that the pharmacovigilance systems 
being developed have the capacity for early identification of potential 
abuse and dependence. The Committee recommended that the 
Secretariat work together with the UMC to continue to use VigiBase to 
support scheduling decisions. The Expert Committee requested that the 
UMC adds, on a trial basis, to its quarterly analysis, those medicines 
with signals for "dependence" and "dependence relatedness" and any 
additional demographic and clinically descriptive data available on 
these medicines from VigiBase. This methodology could also be used 
to assist with analysing the medicines under review by the Committee. 
Further clarification was requested on the manner in which withdrawal 
syndromes are coded and analysed. 
 
The Secretariat and UMC will further work on the best strategy for 
ongoing and periodic data mining for signals relevant to the work of 
the Expert Committee. The results from the analysis of VigiBase data 
will be included on a trial basis in the preparation of the pre-review 
and critical review reports for substances under review by the ECDD.  
 
Finally, the Expert Committee suggested that the Secretariat explore 
the use of poison centre data for postmarketing surveillance of 
controlled substances. 
 
6.3 Balancing medical availability and prevention of abuse of 
medicines manufactured from controlled substances 
 
During its thirty-fourth meeting, the Committee discussed factors 
limiting the availability of controlled substances for medical use, 
including barriers inadvertently created by the application of laws and 
regulations, and requested the WHO Secretariat to suggest including 
on the proposed agenda of the thirty-fifth ECDD meeting, a discussion 
of the impact of scheduling on the balance between medical 
availability of controlled substances and the prevention of abuse (6). 
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The Committee was informed that WHO estimates that 5.5 billion 
people (83% of the world’s population) live in countries with low to 
non-existent access to controlled medicines and have inadequate access 
to treatment for moderate to severe pain. In these countries, each year 
tens of millions of patients are suffering without adequate pain 
management – for instance, 1 million patients with end-stage human 
immunodeficiency virus/acquired immunodeficiency syndrome 
(HIV/AIDS), 5.5 million patients with terminal cancer, 0.8 million 
patients with injuries caused by accidents and violence, and women in 
labour (110 million births each year). 
 
In addition, availability of pharmacological treatment for patients with 
opioid dependence can prevent many new HIV infections, and would 
also result in better health for patients with opioid dependence. 
Equally, maternal deaths could be prevented if emergency obstetric 
medicines were more readily available. Some of these obstetric 
medicines are controlled as precursors. 
 
The Expert Committee took note of this information and considered 
that it is important that different stakeholders, including national 
governments, WHO, other international agencies and health-care 
workers, join forces to make these medicines accessible to all in need, 
while ensuring prevention of diversion and abuse. 
 
The Expert Committee noted that it was important that any policy 
measures adopted by a country to counteract abuse and diversion of 
any substance used therapeutically should specifically target the actual 
mechanisms of diversion and abuse, as established by sound analysis 
of the situation, and should not negatively impact patients’ access to 
adequate treatment. This requires rational prescribing according to 
guidelines. 
 
The Expert Committee also noted the difficulty in establishing policies 
for issues of pain and palliative care, since these are cross-cutting 
topics that may involve many diseases, such as cancer, HIV/AIDS, 
extremely resistant tuberculosis and congenital disease.  
 
Recommendations 
The Expert Committee recommended that WHO continue to promote 
the implementation of its policy guidelines Ensuring balance in 
national policies on controlled substances, Guidance for availability 
and accessibility of controlled medicines (25), as well as the WHO 
Guidelines on the pharmacological treatment of persisting pain in 
children with medical illnesses (26) and the WHO Guidelines on the 
psychosocially assisted pharmacological treatment of opioid 
dependence (27). It further recommended that WHO continue to 
develop guidelines on the management of acute pain and of chronic 
pain in adults. 
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The Expert Committee recommended that WHO continue to promote 
the availability of all controlled medicines listed by the WHO in its 
Model List of essential medicines (17) and its Model List of essential 
medicines for children (19). It should also promote the annual 
submission of adequate estimates for these medicines to the INCB 
using the Guide on estimating requirements for substances under 
international control, developed by the International Narcotics Control 
Board and the World Health Organization for use by the competent 
national authorities (4). If necessary, supplementary estimates should 
be submitted immediately to the INCB throughout the year. 
 
6.4 Improving the process for substance evaluation 
The Secretariat conducted a research project on the evaluation of 
substances since the first drug control conventions with the 
involvement of specialists who had served in the past as experts on the 
ECDD or as technical advisers (E. Danenberg et al., unpublished data, 
2012). The project also focused on the improvement of the process. 
The Expert Committee noted with approval a proposal to put in place a 
process to review each scheduled substance every 20 years. The Expert 
Committee welcomed the intention of the Secretariat to continually 
strengthen the review process by evaluating the evidence using 
systematic rating methodology, such as Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) (28). 
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 Annex  
Developments in terminology: the drug treaties, 
scheduling criteria, and diagnostic terms  
 
A primary task of the Expert Committee on Drug Dependence is to 
provide technical determinations concerning particular substances 
under the provisions of the Single Convention on Narcotic Drugs, 1961 
and the Convention on Psychotropic Substances, 1971. These technical 
determinations are made and documented using specific provisions and 
terms defined in the two Conventions. In the half-century since the 
Single Convention on Narcotic Drugs, 1961 was adopted, there has 
been considerable development in the terminology used to describe 
psychoactive substance use, problems and diagnoses. This annex 
reviews the terminology used in the Conventions, and discusses 
developments in the meaning and application of the terms, and how the 
Expert Committee currently applies the terms in its role under the 
Conventions.  
 
The term “drug dependence” 
 
Previous Expert Committee reports (1, 2) give the following definition 
of drug dependence: “A cluster of physiological, behavioural and 
cognitive phenomena of variable intensity, in which the use of a 
psychoactive drug (or drugs) takes on a high priority. The necessary 
descriptive characteristics are preoccupation with a desire to obtain and 
take the drug and persistent drug-seeking behaviour.” The physical 
phenomena of withdrawal and tolerance are thus included in 
dependence, but are not necessary to it. As the Expert Committee has 
used the term, it is applicable to all relevant psychoactive substances, 
whether licit or illicit, and whether used for medical or non-medical 
purposes.  
 
Dependence was introduced with roughly this meaning at the thirteenth 
meeting of the Expert Committee, to replace the term “addiction” (3). 
However, addiction, as mentioned in the preamble to the Single 
Convention on Narcotic Drugs, 1961, has remained in common use in 
the English language, and there have been calls for its reinstatement as 
a technical term (4). Meanwhile, in English and some other languages 
(5), “addiction” has increasingly taken on a wider meaning and now 
includes behaviours such as addiction to gambling and Internet 
addiction.  
 
A further reason for dropping “addiction” as a technical term has been 
the perception that its connotations are pejorative and stigmatizing. 
This reason also underlies moves away from other terms such as 
“abuse” as technical terms. The stigma around drug use means that 
occasional changes in terminology may be needed to meet the goal of 
humane and respectful treatment of patients. 
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Terminology and concepts concerning drug use and problems also vary 
somewhat across languages and cultures, and attention to this issue is 
needed in the context of a system of drug control which is global in its 
reach.  
 
The main WHO diagnostic terms for substance use disorders, 
“dependence” and “harmful use”, appear likely to remain in the 
forthcoming revision of the International Classification of Diseases.  
 
The term “drug abuse” 
 
“Abuse” is used in both the Single Convention on Narcotic Drugs, 
1961 (Article 3, Section 3) and the Convention on Psychotropic 
Substances, 1971 (Article 2, Section 4b) as part of the criteria to be 
applied by the Expert Committee in deciding on the scheduling of 
substances for control, but the Convention does not define the term. 
 
While the Conventions’ use of the term refers to patterns at a 
population level, the term is often also used to characterize behaviour 
at the individual level. In this context, a previous Expert Committee 
defined drug abuse as “persistent or sporadic excessive drug use 
inconsistent with or unrelated to acceptable medical practice” (6). It 
will be noted that the Expert Committee’s definition mentioned above 
is narrower than common usage of the term “abuse”, which usually 
refers to any nonmedical use. 
 
“Drug abuse” was also used as a technical diagnostic term in earlier 
editions of the International Classification of Diseases, but WHO 
publications had already moved away from using the term in 1975 (7) 
due to its stigmatizing connotations, and it was dropped from the 
International Classification of Diseases in 1992. In interpreting the 
term as used in the Conventions, it is appropriate for the Expert 
Committee to use the broad characterization quoted from the 
Convention on Psychotropic Substances. 
 
 “Dependence potential” and “abuse potential” 
 
Expert Committees have assessed the dependence potential of 
substances in accordance with the criterion of the Convention on 
Psychotropic Substances, 1971 that a drug “has the capacity to produce 
a state of dependence”. While attention is routinely paid to the 
phenomena of withdrawal and tolerance, the Expert Committee has 
generally given priority to the cognitive, behavioural and psychosocial 
dimensions of dependence, although the evidence available on these 
aspects has often been relatively narrow, such as how pleasurable the 
drug is to an experienced drug user.  
 
The Expert Committee has also generally considered “abuse liability” 
or “abuse potential” of the substance (considered as equivalent terms), 
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although some Expert Committees have preferred longer formulations: 
“likelihood of abuse” (8) or “actual abuse and/or evidence of 
likelihood of abuse” (2). Although “the concept of abuse potential 
encompasses all the properties of a drug including, for example, 
chemical, pharmacological, and pharmacokinetic characteristics, as 
well as fads in usage and diversion history” (9), “abuse potential” as 
used in Expert Committee deliberations includes such matters as the 
severity and disabling nature of the intoxication a drug produces, as 
well as its dependence potential and public-health and social problems 
from its use. 
 
Some previous Expert Committees have conceptualized dependence 
and abuse potential as separate concepts side by side, and there have 
also been complaints of the terms being used interchangeably (8), but it 
is more in accord with the frame of reference of the Convention on 
Psychotropic Substances, 1971 to follow the conclusions of the twenty-
seventh (10) and thirty-third meetings of the Expert Committee (2) in 
conceptualizing abuse potential as an overarching concept, with 
dependence potential as a constituent part of it. 
 
The range of public health and social problems to be considered 
 
The Expert Committee presently seeks a wide range of information 
about potential dimensions of public-health and social problems arising 
from use of a particular substance as part of its responsibility for 
assessing abuse potential. These include the nature and sequelae of 
intoxication with the substance, and harm to the individual, for 
instance from overdose, adverse reactions to the drug, and other 
consequences of use for physical and mental health. They also include 
harm which may occur to others as well as to the user, such as drug-
related traffic crashes, hospital emergency department admissions, and 
assaults. An effort is made to take into account whether the harm 
results directly from the drug use or arises from fears and other social 
responses to the drug use. 
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This report presents the recommendations of a WHO Expert 
Committee responsible for reviewing information on psychoactive 
substances to assess the need for their international control. The report 
contains a summary of the Committee’s evaluations of γ-
hydroxybutyric acid (GHB) and ketamine. GHB was recommended to 
be rescheduled from Schedule IV to Schedule II of the Convention on 
Psychotropic Substances. The report also discusses the nine substances 
that were pre-reviewed: dextromethorphan, tapentadol, N-
benzylpiperazine (BZP), 1-(3-trifluoromethylphenyl)piperazine 
(TFMPP), 1-(3-chlorophenyl)piperazine (mCPP), 1-(4-
methoxyphenyl)piperazine (MeOPP), 1-(3,4-
methylenedioxybenzyl)piperazine (MDBP), γ-butyrolactone (GBL), 
and 1,4-butanediol (1,4-BD). Of these, tapentadol, BZP, GBL and 1,4-
BD were recommended for critical review. Issues identified for 
consideration at future Expert Committee meetings are also listed. 
Furthermore, the report discusses the use of terms, the use of 
pharmacovigilance data for the assessment of abuse and dependence 
potential, balancing medical availability and prevention of abuse of 
medicines manufactured from controlled substances, and improving 
the process for substance evaluation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
